GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » EPS (Basic)

KAPA (Kairos Pharma) EPS (Basic) : $-0.25 (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma EPS (Basic)?

Kairos Pharma's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.25.

Kairos Pharma's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.25.

Kairos Pharma's EPS without NRI for the three months ended in Sep. 2024 was $-0.10. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.25.

During the past 3 years, the average EPS without NRI Growth Rate was -21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Kairos Pharma's highest 3-Year average EPS without NRI Growth Rate was -21.80% per year. The lowest was -21.80% per year. And the median was -21.80% per year.

Kairos Pharma EPS (Basic) Historical Data

The historical data trend for Kairos Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma EPS (Basic) Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Basic)
-0.09 -0.10 -0.10 -0.17

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.10 -0.03 -0.02 -0.10

Kairos Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Kairos Pharma's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.812-0)/11.031
=-0.16

Kairos Pharma's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.047-0)/10.910
=-0.10

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma  (AMEX:KAPA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Kairos Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » EPS (Basic)
Comparable Companies
CLCS PHGE SPRB MEIP HCWB AFMD IPA EDSA SABS LPCN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Website
https://kairospharma.com
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.